Venkitaraman et al.[77] demonstrated that glucocorticoids inhibit lymphangiogenesis through vascular endothelial growth factor downregulation and inhibit prostate cancer cell proliferation through the glucocorticoid receptor induction. The gene discussed is NR3C1; the disease is prostate cancer.